Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | PHGDH | O43175 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.49 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11019881 | 0.85 | EGFR (0.59) | EGFRALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL9779133 | 0.82 | ALDH1A1 (0.54) | EGFRALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL11018570 | 0.81 | EGFR (0.65) | EGFRALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL10136106 | 0.81 | GRIN1 (0.52) | EGFRALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL11023598 | 0.80 | KMT2A (0.60) | EGFRALDH1A1MAPTKMT2ALMNA | |
| SCHEMBL3159167 | 0.80 | ALDH1A1 (0.71) | ALDH1A1MAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL793684 | 0.76 | HSD17B10 (0.61) | EGFRALDH1A1MAPTLMNASMN1; SMN2 | |
| SCHEMBL4632544 | 0.75 | ALDH1A1 (0.55) | ALDH1A1MAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL417375 | 0.73 | ALDH1A1 (0.53) | ALDH1A1MAPTKMT2ALMNASMN1; SMN2 | |
| SCHEMBL14982132 | 0.73 | ALDH1A1 (0.61) | ALDH1A1MAPTKMT2ALMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0156785-A1 | 2-(Aminoalkyl)-acrylophenones, their preparation and their use | S.A.R.L. GALEPHAR (FR) | 1985-10-02 | — | — | EP | claimed |
| EP-2819662-B1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2019-04-10 | — | — | EP | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-9552457-B2 | Reprogramming effector protein interactions to correct epigenetic defects in cancer | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2017-01-24 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2015-06-04 | — | — | US | disclosed |
| WO-2013127011-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) | 2013-09-06 | — | — | WO | disclosed |
| EP-0156785-A1 | 2-(Aminoalkyl)-acrylophenones, their preparation and their use | S.A.R.L. GALEPHAR (FR) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150154345-A1 | REPROGRAMMING EFFECTOR PROTEIN INTERACTIONS TO CORRECT EPIGENETIC DEFECTS IN CANCER | CBX2, BPTF, CBX4 | EGFR 2572/4885ALDH1A1 4214/4885MAPT 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.